Article

Stereotactic Body Radiotherapy in the Treatment of Adrenal Metastases.

*Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL †Department of Radiation Oncology, Mayo Clinic, Rochester, MN ‡Department of Radiation Oncology, Providence Medical Center, Kansas City, Kansas.
American journal of clinical oncology (Impact Factor: 2.21). 07/2012; DOI: 10.1097/COC.0b013e3182569189
Source: PubMed

ABSTRACT OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.

0 Bookmarks
 · 
99 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Abdominal compression using a pneumatic abdominal compression belt developed in-house has been used to reduce respiratory motion of patients undergoing hypo-fractionated or single fraction stereotactic radio-ablative therapy for abdominal cancers. The clinical objective of belt usage was to reduce the cranial-caudal (CC) respiratory motion of the tumor to 5 mm or less during both CT simulation and treatment. A retrospective analysis was done to determine the effectiveness of the device and associated clinical procedures to reduce the CC respiratory motion of the tumor. Materials and Methods: 42 patients treated for tumors in the liver (30), adrenal glands (6), pancreas (3) and lymph nodes (3) using high dose hypofractionated radiotherapy between 2004 and the present were eligible for analysis. All patients had 2-3 radiopaque fiducial markers implanted near the tumor prior to simulation, or had clips from prior surgery. Integral to the belt is an inflatable air bladder that is positioned over the abdomen. The pneumatic pressure was set to a level in consultation with the patient. The CC motion was measured fluoroscopically with and without pneumatic pressure. Pneumatic pressure was used at all treatments to reduce to CC motion to that achieved at simulation. Results: The mean CC motion with the belt in place, but no additional air pressure was 11.4 mm with a range of 5-20 mm. With the pressure applied, the mean CC motion was reduced to 4.4 mm with a range of 1-8 mm (P-value < 0.001). The clinical objective of reducing the CC motion of the tumor to a maximum excursion of 5 mm or less was achieved in 93% of cases. Conclusion: The use of a pneumatic compression belt and associated clinical procedures was found to result in a significant and frequently substantial reduction in the CC motion of the tumor.
    Technology in cancer research & treatment 11/2013; DOI:10.7785/tcrt.2012.500379 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic body radiotherapy (SBRT) has been used extensively in patients with lung, liver and spinal tumors, and the treatment outcomes are very favorable. For certain conditions such as medically inoperable stage I non-small-cell lung cancer, liver and lung oligometastases, primary liver cancer and spinal metastases, SBRT is regarded as one of the standard therapies. In the recent years, the use of SBRT has been extended to other disease conditions and sites such as recurrent head and neck cancer, renal cell carcinoma, prostate cancer, adrenal metastasis, pancreatic cancer, gynecological malignancies, spinal cord compression, breast cancer, and stage II-III non-small-cell lung cancer. Preliminary data in the literature show promising results but the follow-up intervals are short for most studies. This paper will provide an overview of these emerging applications.
    Future Oncology 05/2014; 10(7):1299-310. DOI:10.2217/fon.14.13 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review To discuss the emerging roles of stereotactic ablative radiotherapy (SABR) in patients with metastatic renal cell carcinoma (RCC). Recent findings RCC tumours are not as radio-resistant as previously thought, as local control rates of tumours treated with SABR are high. Therefore, SABR is an attractive treatment option for RCC tumours in which effective long-term palliation of symptoms or local control is desired. Like surgical resection of metastatic tumours, SABR can also be used as a method of eradicating oligometastases to potentially 'cure' or offer prolonged disease-free survival in patients with low-volume metastatic disease. In patients who develop progression of a solitary or few tumours (termed oligoprogression), SABR to the progressing 'rogue' tumours may delay the need to start or change systemic therapy. Finally, there is the potential for SABR to improve the efficacy of immunotherapy for metastatic RCC, given the known immune-modulated abscopal effect of radiotherapy. Summary SABR is increasingly being used in metastatic RCC patients, given the great potential to improve various outcomes. More prospective clinical trials are needed to identify and quantify the clinical benefits.
    Current Opinion in Supportive and Palliative Care 07/2014; 8(3). DOI:10.1097/SPC.0000000000000074